ClinicalTrials.gg
WithdrawnNCT05584215CBTpUpdated Oct 9, 2024

Cognitive Behavioural Therapy-Informed Groups for Psychosis

An interventional study of Cognitive Behavioural Therapy for Psychosis Groups in Psychosis, sponsored by London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's. Withdrawn. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-10-09.

Sponsored by London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's · Not applicable, Interventional, and Treatment

Why this study was withdrawn
PI transitioned to new role
Phase
Not applicable
Study type
Interventional
Enrollment
0
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This is a feasibility study of cognitive behavioural therapy-informed groups for psychiatric inpatients with positive symptoms of psychosis.

Read the detailed description

The majority of inpatients at Parkwood Institute Mental Health have symptoms of psychosis. In line with Health Quality Ontario standards for the treatment of psychosis, the investigators would like to implement and evaluate cognitive behavioural therapy for psychosis (CBTp) informed groups. The feasibility, acceptability, and preliminary efficacy of CBTp groups for inpatients will be examined. Pragmatically, the investigators propose to undergo training in CBTp, implement empirically-supported CBTp protocols developed for inpatients, track outcomes, and publish our findings. The investigators would also incorporate patient feedback to improve future iterations of the protocol. Such an undertaking would build research capacity in front line staff by encouraging engagement in CBTp group training, survey design, participant screening, data collection, analyses, and dissemination of findings.

02

Conditions studied

  • Psychosis

Browse trials for

Keywords

  • cognitive behavioral therapy
03

In context

Psychotic Disorders

1,655 studies on the registry are indexed under Psychotic Disorders; 298 are open to participants now.

Browse Psychotic Disorders studies →

Lead sponsor

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's is the lead sponsor of 327 studies on the registry; 132 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Can read/write in English
  • Has positive symptoms of psychosis that are distressing to them

Exclusion criteria

Exclusion Criteria:

  • Inability to tolerate group participation
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Treatment

    Treatment group will receive cognitive behavioural therapy informed groups for psychosis.

    Behavioral: Cognitive Behavioural Therapy for Psychosis Groups

  • No intervention
    Control

    Control group will be put on a waitlist to receive cognitive behavioural therapy informed groups for psychosis.

Interventions

  • BehavioralCognitive Behavioural Therapy for Psychosis Groups

    Groups based on cognitive behavioural therapy for psychosis

06

What researchers measure

Primary outcomes

  1. Clinical Outcomes in Routine Evaluation 10 (CORE-10)

    The Clinical Outcomes in Routine Evaluation 10 is a short 10 item easy-to-use assessment measure for common presentations of psychological distress, designed to be used for screening as well as over the course of treatment to track progress. The minimum value is 0, the maximum value is 40, and higher scores indicate a worse outcome.

    Time frame: Up to 2 months

  2. Process of Recovery Questionnaire (QPR)

    The Process of Recovery Questionnaire is a 15 item questionnaire which was co-produced by people who experience psychosis and their accounts of recovery. The minimum value is 0, the maximum value is 60, and higher scores indicate a better outcome.

    Time frame: Up to 2 months

Secondary outcomes

  1. The Positive and Negative Syndrome Scale (PANSS) - Positive Symptoms

    A brief measure of positive symptoms of psychosis. The minimum value is 7, the maximum values is 49. Higher scores indicate a worse outcome.

    Time frame: Up to 2 months

Other outcomes

  1. Satisfaction Questionnaire

    Brief open-ended questions about program satisfaction. Responses are qualitative.

    Time frame: Up to 2 months

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2023 (actual). Primary completion is estimated for Jan 2024, 6 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 30, 2022
First posted
Oct 18, 2022
StartActual
Jun 3, 2023
Primary completionEst.
Jan 2, 2024
CompletionEst.
Jan 2, 2024
Last update
Oct 9, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 9, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05584215
Responsible party
Serena Wong (Principal Investigator, London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's) — Principal investigator
First posted
Oct 18, 2022
Start date
Jun 3, 2023
Primary completion
Jan 2, 2024 (estimated)
Completion
Jan 2, 2024 (estimated)
Last update
Oct 9, 2024

Study contacts

Serena Wong, PhD
principal investigator · London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion